AltPep

Edit info

Founded: 2018

Location: Seattle, WA

Employee range: 11 - 50

Clinical stage: Clin0

Therapy area: Alzheimer's

Drug types: NEU

Lead product: Sobin Therapeutics

Funding: $53M B Jun 2023

Investors: Senator Investment Group, Section 32, Partners Investment, Eli Lilly and Company, Alexandria Venture Investments, Matrix Capital Management Company

altpep.com

linkedin.com

job board

Business:

Alternating Peptides for Neurological Diseases

Drug notes:

Also RD/Clin0 Parkinson's; Soba diagnostics in development for Alzheimer's & Parkinson's

About:

AltPep is developing treatments and detection tools for amyloid diseases. Unfolded or misfolded proteins can accumulate into harmful deposits that have been linked with neurodegenerative and systemic disorders called amyloid diseases. AltPep identified a novel protein structure, alpha-sheet, using computer modeling techniques that is thought to be causal to misfolded aggregates in over 50 amyloid diseases. Using this knowledge, AltPep has created a platform of de novo synthetic peptides designed to target and neutralize the impact of these misfolded aggregates at the early stages of disease. In addition, AltPep is using the presence of these aggregates to create their SOBA Diagnostic platform that is being investigated for use in Alzheimer’s and Parkinson’s diseases.

Main

Contact: recruit@workinbiotech.com